MX2010002341A - Derivados de bencimidazol usados como agonistas del receptor x de farnesoide. - Google Patents

Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.

Info

Publication number
MX2010002341A
MX2010002341A MX2010002341A MX2010002341A MX2010002341A MX 2010002341 A MX2010002341 A MX 2010002341A MX 2010002341 A MX2010002341 A MX 2010002341A MX 2010002341 A MX2010002341 A MX 2010002341A MX 2010002341 A MX2010002341 A MX 2010002341A
Authority
MX
Mexico
Prior art keywords
benzimidazole derivatives
derivatives used
fxr agonists
fxr
agonists
Prior art date
Application number
MX2010002341A
Other languages
English (en)
Inventor
Sven Taylor
Hans Richter
Jean-Marc Plancher
Uwe Grether
Konrad Bleicher
Rainer E Martin
Gregory Martin Benson
Minmin Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010002341A publication Critical patent/MX2010002341A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a nuevos derivados bencimidazol sustituido de la fórmula (I) (ver fórmula I) en la que de R1 a R10 y X tienen los significados definidos en la descripción y en las reivindicaciones, así como las sales y ésteres fisiológicamente aceptables de los mismos. Estos compuestos se fijan sobre el FXR y pueden utilizarse como medicamentos.
MX2010002341A 2007-08-27 2008-08-19 Derivados de bencimidazol usados como agonistas del receptor x de farnesoide. MX2010002341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115005 2007-08-27
PCT/EP2008/060820 WO2009027264A1 (en) 2007-08-27 2008-08-19 Benzimidazole derivatives used as fxr agonists

Publications (1)

Publication Number Publication Date
MX2010002341A true MX2010002341A (es) 2010-03-22

Family

ID=39967744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002341A MX2010002341A (es) 2007-08-27 2008-08-19 Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.

Country Status (15)

Country Link
US (1) US7790904B2 (es)
EP (1) EP2188263B1 (es)
JP (1) JP5204232B2 (es)
KR (1) KR101237577B1 (es)
CN (1) CN102083799B (es)
AR (1) AR070648A1 (es)
AU (1) AU2008291148B2 (es)
BR (1) BRPI0815696A2 (es)
CA (1) CA2697167C (es)
CL (1) CL2008002506A1 (es)
ES (1) ES2387230T3 (es)
MX (1) MX2010002341A (es)
PE (1) PE20090622A1 (es)
TW (1) TW200916099A (es)
WO (1) WO2009027264A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009062874A2 (en) * 2007-11-15 2009-05-22 F. Hoffmann-La Roche Ag Benzimidazole derivatives and their use as fxr agonists
CN102149688B (zh) 2008-09-11 2014-11-19 霍夫曼-拉罗奇有限公司 新型苯并咪唑衍生物
US8309581B2 (en) * 2009-09-29 2012-11-13 Hoffmann-La Roche Inc. Benzimidazole derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
EP3711762A1 (en) 2013-09-11 2020-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) A farnesoid x receptor agonsits foruse and pharmaceutical compositions for the treatment of chronic hepatitis b virus infection
CN106632065B (zh) * 2016-12-06 2019-08-30 沈阳药科大学 苯并咪唑类化合物及其应用
CN106905241B (zh) * 2017-02-14 2020-03-17 沈阳药科大学 1,2-二取代苯并咪唑衍生物及其应用
BR112019017312A2 (pt) 2017-02-21 2020-04-14 Genfit combinação de um agonista de ppar com um agonista de fxr
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
MX2022000742A (es) 2019-07-18 2022-02-14 Enyo Pharma Metodo para disminuir los efectos adversos del interferon.
MX2022008062A (es) 2020-01-15 2022-07-27 Inst Nat Sante Rech Med Uso del agonista fxr para el tratamiento de una infeccion por el virus de la hepatitis d.
CN111793034B (zh) * 2020-07-24 2021-11-19 华中科技大学 苯并咪唑盐衍生物与制备抗肿瘤药物的应用
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829765A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
CA2530081A1 (en) * 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2655395C (en) * 2006-06-29 2011-10-11 F.Hoffmann-La Roche Ag Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same

Also Published As

Publication number Publication date
KR20100051734A (ko) 2010-05-17
WO2009027264A1 (en) 2009-03-05
US7790904B2 (en) 2010-09-07
KR101237577B1 (ko) 2013-02-26
TW200916099A (en) 2009-04-16
CL2008002506A1 (es) 2009-06-12
JP5204232B2 (ja) 2013-06-05
BRPI0815696A2 (pt) 2016-06-21
ES2387230T3 (es) 2012-09-18
JP2010536915A (ja) 2010-12-02
EP2188263B1 (en) 2012-06-27
CN102083799A (zh) 2011-06-01
EP2188263A1 (en) 2010-05-26
PE20090622A1 (es) 2009-05-16
CA2697167A1 (en) 2009-03-05
AU2008291148A1 (en) 2009-03-05
CN102083799B (zh) 2013-10-16
US20090062356A1 (en) 2009-03-05
AU2008291148B2 (en) 2011-03-17
AR070648A1 (es) 2010-04-28
CA2697167C (en) 2013-07-16

Similar Documents

Publication Publication Date Title
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
MX2010006565A (es) Derivados de benzimidazol sustituido por carboxilo o hidroxilo.
MX2009010567A (es) Derivados de imidazolidinona.
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
MX2010003224A (es) Derivados de biaril sulfonamida.
TW200833324A (en) Sulfonamide derivatives
WO2009062874A3 (en) Benzimidazole derivatives and their use as fxr agonists
TW200616940A (en) Novel hexafluoroisopropanol substituted ether derivatives
IN2012DN03337A (es)
MX2012007536A (es) Derivados de heteroarilo que contienen nitrogeno.
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
MX2009010218A (es) Derivados de aza-piridopirimidinona.
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
UA108640C2 (uk) Похідні n-(імідазопіримідин-7-іл)гетероариламідів та їх застосування як інгібіторів pde10a
MX2010005824A (es) Derivados de aminotiazol.
MX2010001742A (es) Nuevos derivados de piperazina-amida.
MY170878A (en) [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
UA107784C2 (en) Inhibitor of melanin production
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
UA109037C2 (uk) Триазолопіридини
MY155517A (en) Heterocyclic derivatives
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2012003469A (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores fosfodiesterasa 10a.
TW200626527A (en) Novel hexafluoroisopropanol derivatives

Legal Events

Date Code Title Description
FG Grant or registration